Mass spectrometry-based proteomics empowers deep profiling of proteome and protein
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …

Multi-dimensional liquid chromatography (MD-LC) continues to gain in popularity for
applications where conventional one-dimensional liquid chromatography is insufficient to …

The ε4 allele of the apolipoprotein E (APOE) gene, a genetic risk factor for Alzheimer's
disease, is abundantly expressed in both the brain and periphery. Here, we present …

Proteomic studies of human Alzheimer's disease brain tissue have potential to identify
protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 …

Amyloid plaques contain many proteins in addition to beta amyloid (Aβ). Previous studies
examining plaque-associated proteins have shown these additional proteins are important; …

In the past decade, relative proteomic quantification using isobaric labeling technology has
developed into a key tool for comparing the expression of proteins in biological samples …

Biomarkers are assayed to assess biological and pathological status. Recent advances in
high-throughput proteomic technology provide opportunities for developing next generation …

Photothermometric sensing strategies as a powerful point-of-care testing (POCT) method
have attracted great interest in various chem/biosensing fields. Though considerable …

Mass Spectrometry (MS) allows the analysis of proteins and peptides through a variety of
methods, such as Electrospray Ionization-Mass Spectrometry (ESI-MS) or Matrix-Assisted …

Phosphorylation is one of the quickest post-translational modifications that controls
downstream signaling pathways regulating processes like cell proliferation, survival, and …